IRA Portfolio Exposure Intelligence
Know exactly which drugs face Medicare price negotiation, when, and what revenue is at risk.
The problem this solves
Life sciences teams need decisions faster than public data can be cleaned manually. This solution compresses months of preparation into a governed, query-ready product.
VP-level and director-level teams often know which questions matter, but the required data is spread across incompatible FDA, CMS, NIH, EMA, USPTO, literature, ontology, and identity sources.
IRA Portfolio Exposure Intelligence removes the repeated engineering work by delivering the connected tables, bridge keys, and sample queries that your team would otherwise build from scratch.
What you get
Pre-computed IRA small molecule and biologic eligibility clocks with exclusion flags.
Medicare spend trend, beneficiary exposure, and Maximum Fair Price effective-year tracking.
Patent, exclusivity, and biosimilar/generic competition timeline aligned to revenue risk.
Portfolio-level prioritization for market access, finance, and policy teams.
Context Layers Powering This Solution
Each card links to a query-ready context layer in the biomedical estate.
Approval pathways, review history, and regulatory status
Regulatory layer • 400K+ • Monthly
Regulatory contextBiologic competition, biosimilar status, and IRA timing
Regulatory layer • 4K+ products • Monthly
Regulatory contextSmall-molecule approval, patent, exclusivity, and IRA timing
Regulatory layer • 40K+ products • Monthly
Financial & Market Access contextMedicare pharmacy-channel spend and exposure context
Financial & Market Access layer • 5K+ drugs • Annual
Financial & Market Access contextPhysician-administered drug spend and HCPCS exposure context
Financial & Market Access layer • 1K+ HCPCS codes • Annual
Financial & Market Access contextNegotiated price, payment year, and IRA exposure context
Financial & Market Access layer • 25+ negotiated drugs • Annual
IP & Patent contextListed patent runway and challenge context
IP & Patent layer • 15K+ patents • Monthly
IP & Patent contextRegulatory exclusivity shield context
IP & Patent layer • 8K+ exclusivity entries • Monthly
Regulatory contextProduct labeling, clinical identity, and substance mappings
Regulatory layer • 158K+ labels • Weekly
Financial & Market Access contextRetail-to-medical billing bridge context
Financial & Market Access layer • 35K+ crosswalk records • Annual
Day-one query results for apixaban
Designed sample output showing the type of redacted table your analysts can query immediately after provisioning.
| Signal | Value | Source |
|---|---|---|
| Canonical entity | apixaban | Drug spine |
| Primary risk score | High confidence | Pre-computed model |
| Connected products | 10 products | TDD catalog |
| Latest refresh | 2026-09-01 | Lineage table |
Built for the teams who own the decision
For Market Access teams
Quantify exposure by brand, molecule, indication, and Medicare channel before CMS selection windows.
For Portfolio strategy teams
Compare IRA risk against patent cliff, exclusivity, and lifecycle-management options.
For Finance leaders
Stress-test revenue scenarios using Part D, Part B, and negotiated MFP tables.
Common questions
Procurement, architecture, and analytics teams can evaluate exactly how the product will land in your environment.
Query on day one
Sample SQL included
Does the solution include 2026 and 2027 IRA negotiation context?
Yes. CMS IRA Maximum Fair Price records, selected-drug metadata, payment year fields, and eligibility features are delivered with the solution.
Can we model products not yet selected by CMS?
Yes. Eligibility clocks, spend thresholds, biologic versus small molecule rules, orphan flags, and patent context are pre-computed for candidate products.
Is this a dashboard?
No. The output is a set of governed data products delivered into BigQuery or Snowflake so your analytics team can query, model, and integrate freely.
See This Solution In Action
We'll walk through live warehouse queries and sample outputs for your specific use case.
Request Demo